The wnt/β‐catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer

Citations Over TimeTop 10% of 2011 papers

Abstract

Breast cancer continues to be a serious health problem particularly in developed countries. Of particular concern is triple negative breast cancer (TNBC) which does not respond well to standard hormone therapy and is associated with poor overall patient prognosis. Recent studies indicate that Wnt/β-catenin signaling is particularly activated in TNBC, such that the Wnt receptor frizzled-7 (FZD7) and the Wnt co-receptor LRP6 were found to be up regulated in TNBC. In addition, it has been demonstrated that transcriptional knockdown of LRP6 or FZD7 in TNBC cells suppressed tumor growth in vivo. Furthermore, salinomycin, a selective breast cancer stem cell killer, was recently demonstrated to be an inhibitor of Wnt/β-catenin signaling by inducing LRP6 degradation. Therefore, the Wnt/β-catenin signaling pathway and particularly the Wnt receptors on the cell surface may serve as novel therapeutic targets for the treatment of TNBC.

Related Papers

• → Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling(2002)1,029 cited
• → LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling:Arrows point the way(2004)1,027 cited
• → Oligomerization of Frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/β-catenin pathway(2018)72 cited
• → Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize β-catenin independently of Frizzled proteins(2004)105 cited
• → Insights into the Wnt Signaling Pathway Evolution(2022)3 cited